Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixazomib for Kaposi Sarcoma
NCT04305691Phase 2Active, not recruiting
- Sponsor
- AIDS Malignancy Consortium
- Start
- Nov 2023
- Primary completion
- Mar 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ixazomib in Kaposi sarcoma (KS), sponsored by AIDS Malignancy Consortium. Primary endpoint: Overall Response Rate. Started Nov 2023; status: active, not recruiting.
02
Drugs
ixazomib
03
Conditions
Kaposi sarcoma (KS)
Beyond the preview
Go deeper on NCT04305691.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04305691.